MLH1 and neoplasm: Identification of LS is recommended in all endometrial cancer patients, evaluating immunohistochemistry for MMR proteins, unless loss of MLH1 expression is caused by MLH1 promoter hypermethylation, which is likely due to somatic MLH1 mutations within the tumor itself [14].